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osting by EAbstract Purpose: To report the outcomes on the Boston Type 1 Keratoprosthesis at our
institution.
Design: Retrospective analysis case series.
Participants: We analyzed 54 eyes of 53 patients who previously underwent Boston Type 1 Kera-
toprosthesis surgery at our institution from July 2006 to March 2011.
Methods: Preoperative and postoperative parameters were collected and analyzed.
Main outcome measures: Visual acuity and keratoprosthesis stability.
Results: Common preoperative diagnoses were penetrating keratoplasty failure in 49 eyes (90.7%),
chronic keratitis in 2 eyes (3.7%), ocular cicatricial pemphigoid in 1 eye (1.85%), Stevens Johnson
syndrome in 1 eye (1.85%) and corneal vascularization in 1 eye (1.85%). Additionally, 40 eyes
(74%) had preoperative glaucoma, and an Ahmed valve was implanted in 55% of them. Preoper-
ative BCVA ranged from 20/200 to light perception. At an average follow-up of 20.15 months ±
12.7 (range, 1–56), postoperative vision improved to P20/200 in 18 eyes (33.3%) and P20/50 in
4 eyes (7.4%). The graft retention was 96%.tonoma University of Barce-
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/Josep Mª Llado´, 3, 08035
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282 J.L. Gu¨ell et al.Conclusions: The Boston Type 1 keratoprosthesis is a valid option for high-risk patients. The
design improvements in the Boston keratoprosthesis, as well as the daily implementation of the
therapeutic methods, have notably diminished occurrence of the most serious complications, such
as corneal necrosis and endophthalmitis. As such, glaucoma and its subsequent complications now
stand as the most prevalent prognostic factor in the long term.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.Figure 1 The arrow shows initial necrosis: FP = Front Part,
C = Cornea, BP = Back Plate.1. Introduction
Since 1789, when the French surgeon Guillame Pellier de
Quengsy ﬁrst described a corneal prosthesis Pellier de Quen-
gsy, xxxx, there have been numerous attempts to design a ker-
atoprosthesis which fulﬁlls the criteria of biocompatibility and
long term retention, with good visual acuity according to both
patient and ophthalmologist; and which does not call for com-
plex techniques (Barber, 1988). As a result of the multiple pos-
sible complications and the high extrusion rate, the
keratoprosthesis is used only exceptionally. However, recent
years have seen the search for the ideal prototype intensify,
due in part to the high level of graft rejection in high risk pa-
tients (Dandona et al., 1997), the ever growing number of pa-
tients with severe corneal pathology and the lack of donor
tissue.
Moreover, graft failure has become the most widespread
cause of keratoprosthesis indication. Previous studies have
demonstrated that the mean survival periods of the repeated
transplants decreased gradually with the number of regrafting
procedures (Bersudsky et al., 2001). On the other hand, previ-
ous group found that the survival of ﬁrst time grafts was 90%
at 5 years and 82% at 10 years. Initial regrafts had signiﬁcantly
lower 5-year and 10-year survival rates, 53% and 41%, respec-
tively. The highest survival rates were noted in primary grafts
for eyes with a preoperative diagnosis of keratoconus or
Fuchs’ dystrophy (Thompson et al., 2003).
At present, two keratoprostheses are generally accepted by
the ophthalmothologic community; the Boston Type 1 kerato-
prosthesis and the Osteo-Odonto-keratoprosthesis (OOKP).
Both provide acceptable retention levels and good visual re-
sults (Zerbe et al., 2006; Falcinelli et al., 2005). However, the
complexity of the technique required for the implantation of
the latter has led to an exponential increase in the use of the
Boston keratoprosthesis in recent years. In 2002, less that
100 Boston devices were implanted worldwide, while in 2009
about 1200 procedures were reported.
Improvements and modiﬁcations in post-operational ther-
apy have contributed to this increase (Khan et al., 2007). These
design improvements include: the incorporation of a titanium
ring to prevent the intraocular disassembly of the device, the
addition of holes in the posterior plate, improving the diffusion
of nutrients to the graft, a simpliﬁcation of the assembly pro-
cedure which also causes less damage to the donor endothe-
lium and more recently, a new titanium back plate, which is
hoped to improve biocompatibility and retention levels, mini-
mize the damage caused to the corneal tissue, and reduce the
formation of retroprosthetic membranes and stromal necrosis.
Furthermore, the use and regular replacement of a contact
lens (Dohlman et al., 2002), as well as the chronic administra-
tion of broad-spectrum antibiotics (Durand and Dohlman,
2009) specially Vancomicyne (14 mg/ml) (and of antifungalswhere necessary) have minimized the occurrence of the most
serious complications such as stromal necrosis (Fig. 1) and
endophthalmitis.2. Methods
We undertook a retrospective analysis of 54 eyes of 53 patients
who underwent Boston Type 1 keratoprosthesis. We included
all Boston Type 1 keratoprosthesis implantations performed at
the Instituto de Microcirugı´a Ocular (IMO) by two surgeons
(J.L.G–O.G), over a 5 year period (July 2006–March 2011).
Different demographic data, preoperative diagnoses, asso-
ciated pathologies and concomitant surgical procedures were
recorded. The pre and postoperative BCVA were obtained at
each examination, and were measured using a Snellen chart.
All the parameters were registered in an electronic database
for later analysis.3. Results
3.1. Patient demographic
The average length of the follow-up was 20.15 month ± 12.7
(range 1–56). Sixty-one (61%) of the subjects were male and
Thirty-nine (39%) were female. The average age was
58.96 ± 20.35 (range 12–90).
The preoperative diagnoses were penetrating keratoplasty
failure in 49 eyes (90.7%), chronic keratitis in 2 eyes (3.7%),
ocular cicatricial pemphigoid in 1 eye (1.85%), Stevens John-
son syndrome in 1 eye (1.85%) and corneal vascularization
in 1 eye (1.85%) (Table 1). On other hand, the primary diag-
noses in these patients are shown in Table 2.
The preoperative BCVA was 0.015 ± 0.028 (range light
perception to 0.1) (Table 3).
Table 1 Preoperative diagnoses in patients with Boston
Keratoprosthesis.
Preoperative diagnoses No. of eyes %
Graft rejection 49 90.7
Cronic keratitis 2 3.7
Stevens Johnson syndrome 1 1.85
Ocular cicatricial pemphigoid 1 1.85
Corneal vascularization 1 1.85
Table 2 Primary diagnoses in patients with Boston
Keratoprosthesis.
Primary diagnoses No. of eyes %
Pseudophakic keratopathy 11 20.4
Aniridia 8 14.8




Ocular trauma 8 14.8
Cronic keratitis 4 Rosacea 11.1
2 Others
Fuchs’ dystrophy 2 3.7
Congenital cataracts 2 3.7
Glaucoma 2 Cronic 5.5
1 Congenital
Nanophthalmos 2 3.7
Chemical injury 1 1.85
Keratoconus 1 1.85
Stevens Johnson syndrome 1 1.85
Ocular cicatricial pemphigoid 1 1.85
Table 3 Preoperative versus postoperative BCVA in patients
with Boston keratoprosthesis.
BCVA Preoperative Postoperative
No. of eyes % No. of eyes %
P20/20 – – – –
20/25 – – 1 1.85
20/30 – – 1 1.85
20/40 – – 1 1.85
20/50 – – 1 1.85
20/60 – – 1 1.85
20/70 – – – –
20/80 – – – –
20/100 – – 7 13
20/200 4 7.4 6 11.1
20/400 2 3.7 5 9.3
CF 7 13 9 16.7
HM 30 55.6 10 18.5
LP 8 14.8 9 16.6
NLP 3 5.5 3 5.5
CF = counting ﬁngers, HM= hand movements, LP = light per-
ception, NLP = no light perception.
Table 4 Medications used in patients with Boston Type 1
Keratoprosthesis.
No. medications
0 1 2 3
Total of patients (54) 19 12 14 9
Patients with glaucoma (40) 5 12 14 9
Patients with valve (22) 5 3 9 5
Table 5 Digital pressure in patients with Boston Type 1
Keratoprosthesis.
Digital pressure Without valve With valve
N % N %
High 3 5.5 – –
Normal-high 2 3.7 7 13
Normal 18 33.3 7 13
Normal-low 2 3.7 5 9.3
Low 7 13 3 5.5
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Of the keratoprostheses implanted, 72.2% were aphakic mod-
els, and 27.8% were pseudophakic. The concomitant surgicalprocedures were as follows: Ahmed valve implanted in 22 eyes
(40.7%), posterior vitrectomy in 27 eyes (50%), an IOL ex-
plant in 5 eyes (9.3%), and cataract extraction in 1 eye
(1.85%).
3.3. Visual acuity outcome
The postoperative BCVA was 0.097 ± 0.18. Thirty-three
(33%) achieved a BCVAP 0.1 (18 eyes) and 7.4%
achievedP 0.4 (4 eyes) (Table 2). A rapid improvement in
the BCVA was observed. The measurements obtained
3 months after the operation do not differ signiﬁcantly from
the ﬁnal BCVA.
3.4. Keratoprosthesis and glaucoma
Concomitant glaucoma was present in 74% (40 eyes). An
Ahmed valve was implanted in 55% of these patients (22 eyes).
59.1% of these devices (13 eyes) were implanted in the anterior
chamber, and the remaining 40.9% (9 eyes) in the posterior
chamber. 64.8% of the glaucomal patients required one or
more medications in order to control glaucoma, but this per-
centage increased to 77.3% in patients with a valve implant
(Table 4).
The BCVA found in the group of glaucomal patients was
from 0.11 ± 0.19, and in patients with valve implants it was
from 0.087 ± 0.11. The group with the tube implanted in the
anterior chamber obtained a better postoperative BCVA than
the group with the implant in the posterior chamber (0.12 v/s
0.04); however, the former group also presented a better pre-
operative BCVA (0.029 v/s 0.009). After the implantation of
the keratoprosthesis, ocular pressure was monitored digitally
(Rubinfeld et al., 1998), ﬁnding a mere 5.5% (3 cases) with
high levels of tension (Table 5).
4. Discussion
The Boston keratoprosthesis was developed to be implanted in
patients who were not suitable candidates for a traditional cor-
Figure 2 Stevens Johnson syndrome–preoperative.
Figure 3 The same patient, 17 months after surgery.
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keratoprosthesis has demonstrated the capacity for rapid vi-
sual recuperation (Dunlap et al., 2010). However, its long-term
stability is in question.
4.1. Visual acuity outcomes
Our study group is constituted of patients with very limited vi-
sual acuity (preoperative BCVA was 60.1 in 100% of eyes and
60.05 in 93% of cases) and, most of them, with a limited poten-
tial maximal VA. Moreover, 74% of patients presented with
preoperative glaucoma. These ﬁgures are comparable to the
Multicenter Boston Type 1 Keratoprosthesis Study (Zerbe
et al., 2006) (94% with preoperative visual acuity 20/400,
52% with preoperative glaucoma) and to the series by Aldave-
etal (Aldave et al., 2009) (90% with preoperative visual acuity
20/400, 76% with preoperative glaucoma), and Chew et al.
(2009) (86% with preoperative visual acuity 20/400, preopera-
tive glaucoma in 73%). The majority of patients experienced
a rapid visual improvement after receiving the keratoprosthesis
implant. Lack of substantial improvement in most patients can
be put down to concomitant glaucomal or retinal pathology.
4.2. Glaucoma and keratoprosthesis
Despite the technical limitations of intraocular pressure mea-
surement after keratoprosthesis, we have achieved a satisfac-
tory control of intraocular pressure. In our study group, wehave just observed 5.5% of high pressure and 78% of normal
or low pressure. Most of these patients have responded well to
topical therapy or laser diodo cyclophotocoagulation
procedure.
Given the reduced levels of the most severe complications,
such as corneal necrosis and endophthalmitis, glaucoma has
become the most serious challenge to patients who have re-
ceived a keratoprosthesis implant. Given that the evaluation
of glaucoma becomes more difﬁcult after the implantation of
a device, adequate preoperative evaluation is important. This
allows for determining the necessity of a concomitant surgical
procedure to manage glaucoma, which has been the case in a
signiﬁcant number of our patients.
Finally, we must accept that only long term close follow up
of all series, will give all of us a better understanding of the real
rate of long term complications and, hopefully, how to deal
with them and, most important, how to work in presenting
them.
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